GSKNYSEPharmaceutical PreparationsAlso trades as GLAXF
GSK plc
Financials through fiscal 2025, year ended Dec 31, 2025
$49.46−0.05 (-0.10%)
Close on Oct 19, 2026
GSK plc revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | – | – | – | – | £17.73B | £17.06B | £17.55B | £17.27B | £17.28B | £16.10B | – | – |
| Vaccines | – | – | – | – | £6.78B | £6.98B | £7.16B | £5.89B | £5.16B | £4.59B | – | – |
| Consumer Healthcare [member] | – | – | – | £0 | £0 | £122.00M | £9.00B | £7.66B | £7.75B | £7.19B | – | – |
| Commercial Operations | – | – | £30.33B | £29.32B | £24.70B | £24.23B | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | – | – | – | – | – | £7.72B | £7.96B | £8.42B | £8.67B | £7.98B | – |
| Vaccines | – | – | – | – | – | £2.71B | £2.97B | £1.94B | £1.64B | £1.43B | – |
| Consumer Healthcare [member] | – | – | – | – | – | £2.21B | £1.87B | £1.52B | £1.37B | £1.12B | – |
| Pharmaceuticals Research and Development [member] | – | – | – | – | – | -£3.54B | -£3.37B | -£2.68B | -£2.74B | -£2.49B | – |
| Pharmaceuticals Including Research and Development [member] | – | – | – | – | – | £4.19B | £4.60B | £5.74B | £5.93B | £5.49B | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| New And Speciality | – | – | – | – | £9.97B | £8.34B | £7.50B | – | – | – | – | – |
| Sub Total [Member] | – | – | – | £8.96B | £7.29B | £6.97B | – | – | – | – | – | – |
| HIV, oncology, immuno-inflammation, respiratory and other | – | – | £10.20B | £8.96B | £7.29B | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of GSK's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.